Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis.

Bonomini, Mario; Davies, Simon; Kleophas, Werner; Lambie, Mark; Reboldi, Gianpaolo; Liberato, Lorenzo Di; Divino-Filho, Josè Carolino; Heimburger, Olof; Ortiz, Alberto; Povlsen, Johan; Iacobelli, Massimo; Prosdocimi, Tommaso; Arduini, Arduino

Abstract

Peritoneal dialysis adoption and technique survival is affected by limitations related to peritoneal membrane longevity and metabolic alterations. Indeed, almost all peritoneal dialysis fluids exploit glucose as an osmotic agent that rapidly diffuses across the peritoneal membrane, potentially resulting in metabolic abnormalities such as hyperglycemia, hyperinsulinemia, obesity, and hyperlipidemia. Moreover, glucose-degradation products generated during heat sterilization, other than glucose itself, induce significant morphological and functional changes in the peritoneum leading to ultrafiltration failure. The partial substitution of glucose with osmotic agents characterized by a better local and systemic biocompatibility has been suggested as a potential strategy to innovate peritoneal dialysis fluids. The approach aims to minimize glucose-associated toxicity, preserving the peritoneal membrane welfare and counteracting common comorbidities. In this work, we report the clinical trial design of ELIXIR, a phase III randomized, controlled, blinded outcome assessment study comparing Xylocore , an innovative formulation based on Xylitol and l-carnitine, to standard glucose-based regimens, in end-stage kidney disease patients treated with continuous ambulatory peritoneal dialysis; 170 patients will be randomized (1:1) to receive XyloCore or to continue their pre-randomization peritoneal dialysis (PD) therapy with glucose-only PD solutions, for 6 months. The primary study's objective is to demonstrate the noninferiority of XyloCore in terms of Kt/V urea, for which a clinically acceptable noninferiority margin of -0.25 has been determined, assuming that all patients will be treated aiming to a minimum target of 1.7 and an optimal target of 2.0.

Citation

Bonomini, M., Davies, S., Kleophas, W., Lambie, M., Reboldi, G., Liberato, L. D., Divino-Filho, J. C., Heimburger, O., Ortiz, A., Povlsen, J., Iacobelli, M., Prosdocimi, T., & Arduini, A. (2024). Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, https://doi.org/10.1177/08968608241274106

• Journal Article Type: Article
• Acceptance Date: Aug 1, 2024
• Online Publication Date: Aug 28, 2024
• Publication Date: Aug 28, 2024
• Deposit Date: Nov 8, 2024
• Journal: Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
• Print ISSN: 0896-8608
• Publisher: SAGE Publications
• Peer Reviewed: Peer Reviewed
• DOI: https://doi.org/10.1177/08968608241274106
• Keywords: End-stage kidney disease, xylitol, peritoneal dialysis, glucose-sparing, kidney failure-solution, l-carnitine, dialysis
• Public URL: https://keele-repository.worktribe.com/output/920722